{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T18:33:27Z","timestamp":1789583607069,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Yangzhou Social Development Research Project","award":["YZ2023128"],"award-info":[{"award-number":["YZ2023128"]}]},{"name":"Yangzhou Basic Research Program (Joint Special Project) Health and Wellness Category Project","award":["2024-1-02"],"award-info":[{"award-number":["2024-1-02"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02236-8","type":"journal-article","created":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T04:46:00Z","timestamp":1773895560000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of serum uric acid and serum uric acid\/creatinine ratio with metabolic dysfunction-associated fatty liver disease in young adults: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Yue","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junxian","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caifeng","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunmin","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"3","key":"2236_CR1","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"issue":"3","key":"2236_CR2","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jhep.2023.04.036","volume":"79","author":"VW Wong","year":"2023","unstructured":"Wong VW, Ekstedt M, Wong GL, Hagstr\u00f6m H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842\u201352.","journal-title":"J Hepatol"},{"issue":"7","key":"2236_CR3","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3748\/wjg.v30.i7.652","volume":"30","author":"Q-J He","year":"2024","unstructured":"He Q-J, Li Y-F, Zhao L-T, Lin C-T, Yu C-Y, Wang D. Recent advances in age-related metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol. 2024;30(7):652\u201362.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"2236_CR4","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.2337\/dci24-0094","volume":"48","author":"K Cusi","year":"2025","unstructured":"Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, Bardsley JK, Beverly EA, Corbin KD, ElSayed NA, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057\u201382.","journal-title":"Diabetes Care"},{"key":"2236_CR5","unstructured":"Zhou XD, Lian L, Chen QF, Kim SU, Cheuk-Fung Yip T, Petta S, Nakajima A, Tsochatzis E, Shi J, Chan WK, et al. Effect of hypertension on long-term adverse clinical outcomes and liver fibrosis progression in MASLD. J Hepatol. 2025."},{"issue":"1","key":"2236_CR6","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1038\/s41598-025-88685-y","volume":"15","author":"B Liang","year":"2025","unstructured":"Liang B, Qiu X, Huang J, Lu Y, Shen H, Ma J, Chen Y. Nonlinear associations of the hs-CRP\/HDL-C index with metabolic dysfunction-associated steatotic liver disease and advanced liver fibrosis in US adults: insights from NHANES 2017\u20132018. Sci Rep. 2025;15(1):4029.","journal-title":"Sci Rep"},{"issue":"1","key":"2236_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/liv.15725","volume":"44","author":"D Clayton-Chubb","year":"2024","unstructured":"Clayton-Chubb D, Kemp WW, Majeed A, Lubel JS, Woods RL, Tran C, Ryan J, Hodge A, Schneider HG, McNeil JJ, et al. Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage. Liver Int. 2024;44(1):39\u201351.","journal-title":"Liver Int"},{"issue":"1","key":"2236_CR8","first-page":"149","volume":"56","author":"Y Chang","year":"2025","unstructured":"Chang Y, Li J, Wu G, Zhang J, Guo B, Zhao X. [Different Types of Obesity Play a Modifying Role in the Association Between Physical Activity and Metabolic Dysfunction-Associated Fatty Liver Disease]. Sichuan Da Xue Xue Bao Yi Xue Ban. 2025;56(1):149\u201355.","journal-title":"Sichuan Da Xue Xue Bao Yi Xue Ban"},{"key":"2236_CR9","doi-asserted-by":"publisher","first-page":"1568211","DOI":"10.3389\/fmed.2025.1568211","volume":"12","author":"B Xu","year":"2025","unstructured":"Xu B, Li H, Pi Y, Li K. Global, regional and national burden of Metabolic dysfunction-associated steatotic liver disease in adolescents and adults aged 15\u201349 years from 1990 to 2021: results from the 2021 Global Burden of Disease study. Front Med (Lausanne). 2025;12:1568211.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"2236_CR10","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1186\/s41043-025-00973-5","volume":"44","author":"Z Sarkoohi","year":"2025","unstructured":"Sarkoohi Z, Bastan MM, Khajuei Gharaei MA, Iranmanesh M, Adinepour A, Khajezade R, Bahri F, Akhlaghi F, Kadkhodamanesh A, Pourghadamyari H, et al. Epidemiological trends and burden of metabolic dysfunction-associated steatotic liver disease in the Middle East and North Africa region: a 32-year analysis of health impact. J Health Popul Nutr. 2025;44(1):207.","journal-title":"J Health Popul Nutr"},{"issue":"4","key":"2236_CR11","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1002\/hep.30702","volume":"70","author":"F Zhou","year":"2019","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H. Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta-Analysis. Hepatology. 2019;70(4):1119\u201333.","journal-title":"Hepatology"},{"issue":"5","key":"2236_CR12","first-page":"e84659","volume":"17","author":"JK Appiah","year":"2025","unstructured":"Appiah JK, Danso EA, Donneyong E. Rising Mortality From Chronic Liver Disease in Young US Adults: A Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER)-Based Analysis. Cureus. 2025;17(5):e84659.","journal-title":"Cureus"},{"key":"2236_CR13","doi-asserted-by":"publisher","first-page":"101003","DOI":"10.1016\/j.ajpc.2025.101003","volume":"22","author":"QZ Li","year":"2025","unstructured":"Li QZ, Tan JX, Qin QZ, Ruan GT, Deng T, Gong YZ. Association between arterial stiffness and MASLD in US young adults: base on NHANES 2005\u20132018. Am J Prev Cardiol. 2025;22:101003.","journal-title":"Am J Prev Cardiol"},{"issue":"4","key":"2236_CR14","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3350\/cmh.2024.0562","volume":"30","author":"JH Bae","year":"2024","unstructured":"Bae JH. Racial and ethnic disparities in metabolic dysfunction-associated steatotic liver disease outcomes: A call for culturally sensitive interventions: Editorial on Differences in liver and mortality outcomes of non-alcoholic fatty liver disease by race and ethnicity: A longitudinal real-world study. Clin Mol Hepatol. 2024;30(4):665\u20138.","journal-title":"Clin Mol Hepatol"},{"issue":"2","key":"2236_CR15","doi-asserted-by":"publisher","first-page":"101898","DOI":"10.1016\/j.aohep.2025.101898","volume":"30","author":"C Kan","year":"2025","unstructured":"Kan C, Zhang K, Wang Y, Zhang X, Liu C, Ma Y, Hou N, Huang N, Han F, Sun X. Global burden and future trends of metabolic dysfunction-associated Steatotic liver disease: 1990\u20132021 to 2045. Ann Hepatol. 2025;30(2):101898.","journal-title":"Ann Hepatol"},{"issue":"1","key":"2236_CR16","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1002\/jpn3.12219","volume":"79","author":"BJ Perumpail","year":"2024","unstructured":"Perumpail BJ, Manikat R, Wijarnpreecha K, Cholankeril G, Ahmed A, Kim D. The prevalence and predictors of metabolic dysfunction-associated steatotic liver disease and fibrosis\/cirrhosis among adolescents\/young adults. J Pediatr Gastroenterol Nutr. 2024;79(1):110\u20138.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"2236_CR17","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jare.2017.03.003","volume":"8","author":"R El Ridi","year":"2017","unstructured":"El Ridi R, Tallima H. Physiological functions and pathogenic potential of uric acid: A review. J Adv Res. 2017;8(5):487\u201393.","journal-title":"J Adv Res"},{"key":"2236_CR18","doi-asserted-by":"crossref","unstructured":"Yanai H, Adachi H, Hakoshima M, Iida S, Katsuyama H. Metabolic-dysfunction-associated steatotic liver disease-its pathophysiology, association with atherosclerosis and cardiovascular disease, and treatments. Int J Mol Sci. 2023;24(20).","DOI":"10.3390\/ijms242015473"},{"issue":"6","key":"2236_CR19","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1080\/00365521.2025.2490994","volume":"60","author":"X Wang","year":"2025","unstructured":"Wang X, Leng S. Serum uric acid may be a mediator of risk factors in metabolic dysfunction associated steatotic liver disease. Scand J Gastroenterol. 2025;60(6):581\u20137.","journal-title":"Scand J Gastroenterol"},{"issue":"4","key":"2236_CR20","doi-asserted-by":"publisher","first-page":"e152","DOI":"10.1016\/j.jhep.2023.12.009","volume":"80","author":"L He","year":"2024","unstructured":"He L, Qiu K, Zheng W, Kong W, Zeng T. Uric acid may serve as the sixth cardiometabolic criterion for defining MASLD. J Hepatol. 2024;80(4):e152\u20133.","journal-title":"J Hepatol"},{"key":"2236_CR21","doi-asserted-by":"publisher","first-page":"3007","DOI":"10.2147\/DMSO.S427070","volume":"16","author":"D She","year":"2023","unstructured":"She D, Xu W, Liu J, Zhang Z, Fang P, Li R, Kong D, Xuan M, Liu Q, Pan MY, et al. Serum Uric Acid to Creatinine Ratio and Risk of Metabolic Syndrome in Patients with Overweight\/Obesity. Diabetes Metab Syndr Obes. 2023;16:3007\u201317.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2236_CR22","doi-asserted-by":"publisher","first-page":"18412","DOI":"10.1038\/s41598-022-22025-2","volume":"12","author":"E Raya-Cano","year":"2022","unstructured":"Raya-Cano E, Vaquero-Abell\u00e1n M, Molina-Luque R, De Pedro-Jim\u00e9nez D, Molina-Recio G, Romero-Salda\u00f1a M. Association between metabolic syndrome and uric acid: a systematic review and meta-analysis. Sci Rep. 2022;12(1):18412.","journal-title":"Sci Rep"},{"key":"2236_CR23","doi-asserted-by":"publisher","first-page":"1060442","DOI":"10.3389\/fendo.2022.1060442","volume":"13","author":"D Zhong","year":"2022","unstructured":"Zhong D, Liu D, Guo Y, Huang H, Li L, Wu F, Huang S. Association of the serum uric acid to creatinine ratio with metabolic syndrome in the middle age and older population in China. Front Endocrinol (Lausanne). 2022;13:1060442.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2236_CR24","doi-asserted-by":"publisher","first-page":"155937","DOI":"10.1016\/j.metabol.2024.155937","volume":"157","author":"M Huttasch","year":"2024","unstructured":"Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? Metabolism. 2024;157:155937.","journal-title":"Metabolism"},{"key":"2236_CR25","doi-asserted-by":"crossref","unstructured":"M\u00e9ndez-Garc\u00eda LA, Escobedo G, Baltazar-P\u00e9rez I, Ocampo-Aguilera NA, Arreola-Miranda JA, Cid-Soto MA, Alfaro-Cruz A, Gonz\u00e1lez-Ch\u00e1vez A, Oca\u00f1a-Guzm\u00e1n AR, Solleiro-Villavicencio H. Exploring the Th2 response in obesity and metabolic dysfunction-associated steatotic liver disease (MASLD): a potential modulator of the renin-angiotensin System (RAS) pathway in hypertension development. Life (Basel). 2024;14(9).","DOI":"10.3390\/life14091080"},{"key":"2236_CR26","doi-asserted-by":"publisher","first-page":"111846","DOI":"10.1016\/j.diabres.2024.111846","volume":"217","author":"S Gancheva","year":"2024","unstructured":"Gancheva S, Roden M, Castera L. Diabetes as a risk factor for MASH progression. Diabetes Res Clin Pract. 2024;217:111846.","journal-title":"Diabetes Res Clin Pract"},{"key":"2236_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.athplu.2023.08.001","volume":"53","author":"M Hoekstra","year":"2023","unstructured":"Hoekstra M, Van Eck M. High-density lipoproteins and non-alcoholic fatty liver disease. Atheroscler Plus. 2023;53:33\u201341.","journal-title":"Atheroscler Plus"},{"key":"2236_CR28","doi-asserted-by":"publisher","first-page":"1294267","DOI":"10.3389\/fmed.2023.1294267","volume":"10","author":"G Rao","year":"2023","unstructured":"Rao G, Peng X, Li X, An K, He H, Fu X, Li S, An Z. Unmasking the enigma of lipid metabolism in metabolic dysfunction-associated steatotic liver disease: from mechanism to the clinic. Front Med (Lausanne). 2023;10:1294267.","journal-title":"Front Med (Lausanne)"},{"issue":"4","key":"2236_CR29","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.jhep.2015.11.022","volume":"64","author":"X Wan","year":"2016","unstructured":"Wan X, Xu C, Lin Y, Lu C, Li D, Sang J, He H, Liu X, Li Y, Yu C. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. J Hepatol. 2016;64(4):925\u201332.","journal-title":"J Hepatol"},{"key":"2236_CR30","doi-asserted-by":"crossref","unstructured":"Shin JW, Sull JW, Minh NT, Jee SH. Prostate cancer risk and antioxidant biomarkers: the age-dependent reversal of bilirubin\u2019s role. BMC Urol. 2025.","DOI":"10.1186\/s12894-025-02029-6"},{"key":"2236_CR31","doi-asserted-by":"crossref","unstructured":"Shin JW, Sull JW, Minh NT, Jee SH. Bilirubin Metabolism and Thyroid Cancer: Insights from ALBI and PALBI Indices. Biomolecules 2025;15(7).","DOI":"10.3390\/biom15071042"},{"issue":"1","key":"2236_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12964-024-01965-4","volume":"23","author":"L Xu","year":"2025","unstructured":"Xu L, Li C, Wan T, Sun X, Lin X, Yan D, Li J, Wei P. Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases. Cell Commun Signal. 2025;23(1):4.","journal-title":"Cell Commun Signal"},{"key":"2236_CR33","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2147\/CLEP.S403314","volume":"15","author":"Q Sun","year":"2023","unstructured":"Sun Q, Zhang T, Manji L, Liu Y, Chang Q, Zhao Y, Ding Y, Xia Y. Association Between Serum Uric Acid and Non-Alcoholic Fatty Liver Disease: An Updated Systematic Review and Meta-Analysis. Clin Epidemiol. 2023;15:683\u201393.","journal-title":"Clin Epidemiol"},{"issue":"2","key":"2236_CR34","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1093\/gastro\/goaa085","volume":"9","author":"QJ Luo","year":"2021","unstructured":"Luo QJ, Sun MX, Guo YW, Tan SW, Wu XY, Abassa KK, Lin L, Liu HL, Jiang J, Wei XQ. Sodium butyrate protects against lipopolysaccharide-induced liver injury partially via the GPR43\/ \u03b2-arrestin-2\/NF-\u03baB network. Gastroenterol Rep (Oxf). 2021;9(2):154\u201365.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"1","key":"2236_CR35","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12876-025-03666-9","volume":"25","author":"Z Chang","year":"2025","unstructured":"Chang Z, Liu Z. Serum uric acid as a biomarker for metabolic dysfunction-associated steatotic liver disease: insights from ultrasound elastography in a Chinese cohort. BMC Gastroenterol. 2025;25(1):94.","journal-title":"BMC Gastroenterol"},{"issue":"12","key":"2236_CR36","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1016\/j.numecd.2024.09.015","volume":"34","author":"W Chen","year":"2024","unstructured":"Chen W, Deng Y, Li M, Li J, Cao Y, Xie W. Serum uric acid and mortality in metabolic dysfunction-associated steatotic liver disease: Subgroup differences. Nutr Metab Cardiovasc Dis. 2024;34(12):2771\u20138.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"12","key":"2236_CR37","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","volume":"30","author":"A Cherubini","year":"2024","unstructured":"Cherubini A, Della Torre S, Pelusi S, Valenti L. Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease. Trends Mol Med. 2024;30(12):1126\u201336.","journal-title":"Trends Mol Med"},{"issue":"1","key":"2236_CR38","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12876-025-03917-9","volume":"25","author":"Y Cui","year":"2025","unstructured":"Cui Y, Qu Z, Li L, Hu W. Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes. BMC Gastroenterol. 2025;25(1):322.","journal-title":"BMC Gastroenterol"},{"key":"2236_CR39","doi-asserted-by":"crossref","unstructured":"Shin JW, Minh NT, Jee SH. Sex-Specific Associations of total bilirubin, ALBI, and PALBI with lung cancer risk: interactions with smoking and alcohol. Healthc (Basel) 2025;13(11).","DOI":"10.3390\/healthcare13111321"},{"key":"2236_CR40","doi-asserted-by":"crossref","unstructured":"Shin JW, Nguyen TM, Jee SH. Association Between Creatinine and Lung Cancer Risk in Men Smokers: A Comparative Analysis with Antioxidant Biomarkers from the KCPS-II Cohort. Antioxid (Basel) 2025;14(5).","DOI":"10.3390\/antiox14050584"},{"issue":"7","key":"2236_CR41","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1089\/met.2019.0024","volume":"17","author":"K Moriyama","year":"2019","unstructured":"Moriyama K. The Association Between the Serum Uric Acid to Creatinine Ratio and Metabolic Syndrome, Liver Function, and Alcohol Intake in Healthy Japanese Subjects. Metab Syndr Relat Disord. 2019;17(7):380\u20137.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"2236_CR42","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s12876-025-03598-4","volume":"25","author":"N Li","year":"2025","unstructured":"Li N, Liu C, Lu Z, Wu W, Zhang F, Qiu L, Shen C, Sheng D, Liu Z. Establishing of a risk prediction model for metabolic dysfunction-associated steatotic liver disease: a retrospective cohort study. BMC Gastroenterol. 2025;25(1):39.","journal-title":"BMC Gastroenterol"},{"key":"2236_CR43","doi-asserted-by":"publisher","first-page":"6928117","DOI":"10.1155\/2023\/6928117","volume":"2023","author":"J Liu","year":"2023","unstructured":"Liu J, Peng H, Wang C, Wang Y, Wang R, Liu J, Zhou T, Yao S. Correlation between the Severity of Metabolic Dysfunction-Associated Fatty Liver Disease and Serum Uric Acid to Serum Creatinine Ratio. Int J Endocrinol. 2023;2023:6928117.","journal-title":"Int J Endocrinol"},{"issue":"1","key":"2236_CR44","doi-asserted-by":"publisher","first-page":"26941","DOI":"10.1038\/s41598-025-09073-0","volume":"15","author":"F Wang","year":"2025","unstructured":"Wang F, Zheng X, Ni X, Li Y. Increased serum uric acid to creatinine ratio is associated with metabolic dysfunction associated steatotic liver disease. Sci Rep. 2025;15(1):26941.","journal-title":"Sci Rep"},{"key":"2236_CR45","doi-asserted-by":"crossref","unstructured":"Mantovani A, Scorletti E, Mosca A, Alisi A, Byrne CD, Targher G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism. 2020;111s:154170.","DOI":"10.1016\/j.metabol.2020.154170"},{"key":"2236_CR46","doi-asserted-by":"publisher","first-page":"102727","DOI":"10.1016\/j.canep.2024.102727","volume":"94","author":"JW Shin","year":"2025","unstructured":"Shin JW, Kim N, Minh NT, Chapagain DD, Jee SH. Serum bilirubin subgroups and cancer risk: Insights with a focus on lung cancer. Cancer Epidemiol. 2025;94:102727.","journal-title":"Cancer Epidemiol"},{"issue":"9","key":"2236_CR47","doi-asserted-by":"publisher","first-page":"e2335511","DOI":"10.1001\/jamanetworkopen.2023.35511","volume":"6","author":"C Liu","year":"2023","unstructured":"Liu C, Liu T, Zhang Q, Jia P, Song M, Zhang Q, Ruan G, Ge Y, Lin S, Wang Z, et al. New-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk. JAMA Netw Open. 2023;6(9):e2335511\u20132335511.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"2236_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12902-025-01860-0","volume":"25","author":"M Oh","year":"2025","unstructured":"Oh M, Cho SH. Serum uric acid to creatinine ratio as a predictor of insulin resistance, \u03b2 cell function, and metabolic syndrome in normal Korean adults: a cross-sectional study. BMC Endocr Disord. 2025;25(1):31.","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"2236_CR49","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","volume":"63","author":"European Association for the Study of the L","year":"2015","unstructured":"European Association for the Study of the L. Asociacion Latinoamericana para el Estudio del H: EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237\u201364.","journal-title":"J Hepatol"},{"issue":"1","key":"2236_CR50","doi-asserted-by":"publisher","first-page":"100873","DOI":"10.1016\/j.aohep.2022.100873","volume":"28","author":"D Contreras","year":"2023","unstructured":"Contreras D, Gonz\u00e1lez-Rocha A, Clark P, Barquera S, Denova-Guti\u00e9rrez E. Diagnostic accuracy of blood biomarkers and non-invasive scores for the diagnosis of NAFLD and NASH: Systematic review and meta-analysis. Ann Hepatol. 2023;28(1):100873.","journal-title":"Ann Hepatol"},{"issue":"1","key":"2236_CR51","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s12902-025-02074-0","volume":"25","author":"A El-Sehrawy","year":"2025","unstructured":"El-Sehrawy A, Alshkarchy SS, Kareem AK, Maashi MS, Al-Khafaji ZA, Hjazi A, Hsu CY, Kadhum WR, Jafarzadeh F. Association between serum uric acid to creatinine ratio with metabolic profile in subjects with non-alcoholic fatty liver disease (NAFLD). BMC Endocr Disord. 2025;25(1):260.","journal-title":"BMC Endocr Disord"},{"key":"2236_CR52","doi-asserted-by":"crossref","unstructured":"Gherghina ME, Peride I, Tiglis M, Neagu TP, Niculae A, Checherita IA. Uric acid and oxidative stress-relationship with cardiovascular, metabolic, and renal impairment. Int J Mol Sci 2022;23(6).","DOI":"10.3390\/ijms23063188"},{"issue":"Suppl","key":"2236_CR53","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","volume":"31","author":"ZM Younossi","year":"2025","unstructured":"Younossi ZM, Kalligeros M, Henry L. Epidemiology of metabolic dysfunction-associated steatotic liver disease. Clin Mol Hepatol. 2025;31(Suppl):S32\u201350.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2236_CR54","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s13098-025-01802-9","volume":"17","author":"Z Jin","year":"2025","unstructured":"Jin Z, Zeng C, Yang Y, Zhong S, Zhou Z. Decoding survival in MASLD: the dominant role of metabolic factors. Diabetol Metab Syndr. 2025;17(1):226.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2236_CR55","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202\u20139.","journal-title":"J Hepatol"},{"issue":"6","key":"2236_CR56","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/j.jhep.2024.02.026","volume":"80","author":"A Di Sessa","year":"2024","unstructured":"Di Sessa A, Guarino S, Umano GR, Miraglia del Giudice E, Marzuillo P. Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J Hepatol. 2024;80(6):e254\u20135.","journal-title":"J Hepatol"},{"issue":"6","key":"2236_CR57","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1016\/j.jhep.2015.01.019","volume":"62","author":"C Xu","year":"2015","unstructured":"Xu C, Wan X, Xu L, Weng H, Yan M, Miao M, Sun Y, Xu G, Dooley S, Li Y, et al. Xanthine oxidase in non-alcoholic fatty liver disease and hyperuricemia: One stone hits two birds. J Hepatol. 2015;62(6):1412\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"2236_CR58","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s10735-025-10507-2","volume":"56","author":"N Gupta","year":"2025","unstructured":"Gupta N, Singh K. Exploring the role of xanthine oxidase and aldehyde oxidase in metabolic dysfunction-associated steatotic liver disease (MASLD). J Mol Histol. 2025;56(4):237.","journal-title":"J Mol Histol"},{"key":"2236_CR59","doi-asserted-by":"crossref","unstructured":"Al-Shargi A, El Kholy AA, Adel A, Hassany M, Shaheen SM. Allopurinol versus febuxostat: a new approach for the management of hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Biomedicines. 2023;11(11).","DOI":"10.3390\/biomedicines11113074"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02236-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02236-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02236-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T01:03:30Z","timestamp":1777338210000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02236-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,19]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2236"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02236-8","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,19]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies were in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The ethical approval for this study was provided by the Ethical Committee of Northern Jiangsu People\u2019s Hospital.(No.2022ky012). Due to the retrospective nature of the study, the committee has waived written informed consent, and the above-mentioned reference number for ethical approval and the statement of waived consent are provided.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}